Literature DB >> 34969738

Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer.

Teppei Kamada1,2, Hironori Ohdaira3, Eisaku Ito3,2, Yoshinobu Fuse3,2, Junji Takahashi3,2, Keigo Nakashima3,2, Yuichi Nakaseko3,2, Masashi Yoshida3, Ken Eto2, Yutaka Suzuki3.   

Abstract

BACKGROUND/AIM: The impact of masseter muscle sarcopenia on the prognosis of patients with oesophageal cancer after oesophagectomy remains unclear. PATIENTS AND METHODS: We retrospectively analysed data from 70 patients with oesophageal cancer who underwent oesophagectomy between 2013 and 2019. Overall survival and disease-free survival rates were analysed using Cox proportional hazards models and Kaplan-Meier curves with the log-rank test.
RESULTS: Masseter muscle sarcopenia was diagnosed in 36 patients. Multivariate analysis identified cytokeratin 19 fragment >1.1 (p=0.04); stage II, III, and IV cancer (p=0.01); and masseter muscle sarcopenia (p<0.01) as significant independent predictors of disease-free survival. Stage II, III, and IV cancer (p<0.01); masseter muscle sarcopenia (p<0.01); and postoperative pneumonia (p<0.01) were significant independent predictors of overall survival.
CONCLUSION: Preoperative masseter muscle sarcopenia could be a strong predictor of long-term outcomes in patients who undergo oesophagectomy for oesophageal cancer.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Oesophageal cancer; masseter muscle; prognosis; psoas muscle; sarcopenia

Mesh:

Year:  2022        PMID: 34969738     DOI: 10.21873/anticanres.15486

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus.

Authors:  Yoshihiro Shimono; Hirayuki Enomoto; Nobuhiro Aizawa; Tomoyuki Takashima; Naoto Ikeda; Yukihisa Yuri; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Ryota Nakano; Hideyuki Shiomi; Takashi Nishimura; Hiroko Iijima
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.